 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Latest Ratings for RXRX
 DateFirmActionFromTo Mar 2022SVB LeerinkDowngradesOutperformMarket Perform Dec 2021SVB LeerinkMaintainsOutperform Sep 2021BerenbergInitiates Coverage OnBuy
 View More...

Analyst Scoreboard: 5 Ratings For Recursion Pharmaceuticals

Recursion Pharmaceuticals Inc Director Blake Borgeson Sells 11,447 Shares

SALT LAKE CITY, April 02, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its...

Recursion to Participate in Upcoming Investor Conference

For the last three days, A.I.dvisor has detected that RXRX's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

Recursion Pharmaceuticals (RXRX, $9.38) Aroon Indicator entered a Downtrend on April 01, 2024.

In trading on Tuesday, shares of Recursion Pharmaceuticals Inc (RXRX) crossed below their 200 day moving average of 9.32, changing hands as low as 8.67 per share. Recursion Pharmaceuticals...

Recursion Pharmaceuticals Breaks Below 200-Day Moving Average - Notable for RXRX

Poseida Therapeutics (NASDAQ:PSTX  Get Free Report) and Recursion Pharmaceuticals (NASDAQ:RXRX  Get Free Report) are both medical companies, but which is the superior investment? We...

Recursion Pharmaceuticals (NASDAQ:RXRX) and Poseida Therapeutics (NASDAQ:PSTX) Critical Review

Provides progress updates in support of long-term commitments focused on reducing greenhouse gas emissions, improving workforce diversity and accelerating community impact.SALT LAKE CITY, March 26...

Recursion Publishes Annual Environmental, Social and Governance Report

Recursion Pharmaceuticals Inc Director Blake Borgeson Sells 20,054 Shares

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX  Get Free Report)s stock price gapped down before the market opened on Tuesday . The stock had previously closed at $11.42, but opened at...

Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Down to $11.42

SoundHound AI, Arm, Nanox Imaging, and Recursion Pharmaceuticals have surged since Nvidia reported investing in them

 Bloomberg / Contributor / Getty Images

 Key TakeawaysSoundHound AI shares...

Since Nvidia Disclosed Stakes in These Stocks, They've Soared

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.

Volume (M)	4.01M
52-Wk High	$16.75
52-Wk Low	$4.54

RXRX Recursion Pharmaceuticals Inc - Ordinary Shares - Class A

About

Feed

News

Sentiment

Earnings

Fundamentals